Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bipolar androgen therapy in mCRPC after progression on abiraterone or docetaxel
ChiCTR2200061643Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of testosterone in metastatic castration-resistant prostate cancer (mCRPC), sponsored by West China Hospital of Sichuan University. Primary endpoints: PSA 50 response and PSA progression-free survival. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
testosterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on ChiCTR2200061643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061643.